Biotech | October 18, 2021
U.S. FDA advisory committee recommends J&J booster dose
U.S. FDA to decide whether to authorize a booster dose in the coming days
U.S. FDA to decide whether to authorize a booster dose in the coming days
The interim analysis showed that the MVC-COV1901 vaccine has a good safety profile and elicits promising neutralising antibody titres
_256_384.jpg)
The two doses of Covaxin are likely to be administered to children with a gap of 28 days
If authorized, molnupiravir could be the first oral antiviral medicine for the treatment of Covid-19
The company has already received the emergency use authorization (EUA) from the Drug Controller General of India (DCGI) for ZyCoV-D to be administered in three doses on August 20
Bharat Biotech has been submitting data to the WHO on a rolling basis and submitted additional information at WHO’s request on September 27th 2021
It is a recombinant nanoparticle protein-based vaccine
Emergency Use Authorisation (EUA) is granted for individuals 65 years of age and older, and individuals ages 18 through 64 within certain high-risk groups
MeMed BV is a first-of-its-kind test that decodes the immune response to accurately distinguish between bacterial or viral infections within minutes
This procedure is incidentally the first robotic bariatric surgery in the world to be performed in just three ports
Subscribe To Our Newsletter & Stay Updated
